SUSPECT ADVERSE REACTION REPORT

SV-TOLMAR, INC.-23SV043287

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	4-6 REACTION ONSET		
		Day	Month	Year	Years		Day	Month	Year
OAPC	EL Cont..	24	Feb	1945	80	Male		Aug	2023

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING (Sensation of heat (10039999), Feeling hot (10016334))
(/Aug/2023 -) - Not Recovered/Not Resolved/Ongoing
2) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING (Sweating (10042661), Hyperhidrosis (10020642))
(/Aug/2023 -) - Not Recovered/Not Resolved/Ongoing
3) Discontinuation of medication (Therapy cessation (10065154), Therapy cessation (10065154))
(28/Mar/2025 -) - Unknown

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)(Unknown) Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (22.5 milligram(s), 1 in 3 Month)
2) (22.5 milligram(s), 1 in 3 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous
2) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) prostate cancer [10007113 - Cancer of prostate]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (03/Jul/2023 -)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CANCER OF PROSTATE (10060862, Prostate cancer) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1-9702124900

Study Information

Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	SV-TOLMAR, INC.-23SV043287
24c. DATE RECEIVED BY MANUFACTURER	**24d. REPORT SOURCE**
06/Aug/2025	☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT	**25a. REPORT TYPE**
14/Aug/2025	☐ INITIAL ☑ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

1a. COUNTRY

EL SALVADOR

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This Study report from EL SALVADOR was received by Adium via Patient Support Program "ASOFARMA A TU LADO" (reference number: SV-ADIUM-SV-0036-20230911) on 11-SEP-2023 from a Consumer regarding a 78 Years old Male patient who received radiotherapy for prostate cancer (Prostate cancer) and began to feel very hot (sensation of heat) and sweating (Sensation of heat and Sweating), during Eligard (Leuprolide acetate) 22.5 milligram therapy for Cancer of prostate. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 11-SEP-2023.

The patient's medical history was not reported. Current conditions included Prostate cancer.

Concomitant medications were not reported.

In AUG-2023 (reported as 20 days ago), the patient began receiving Eligard 22.5 milligram, q 3 month, via Subcutaneous use, for Cancer of prostate (Lot details unknown) and on this same date, 20 days ago, he began to feel very hot (sensation of heat) and sweating, which was discussed with the doctor, indicating that these symptoms were side effects of Eligard's medication and that with time they would disappear. Afterwards, on September 11, 2023 he started the first radiotherapy for prostate cancer, and it was not indicated how many were left.

Corrective treatment included Radiotherapy.

Action taken with Eligard in response to the events was Dose Not Changed. De-challenge and re-challenge were not applicable.

The outcome of Prostate cancer was Not Recovered. The outcome of Sensation of heat was Not Recovered. The outcome of Sweating was Not Recovered.

The reporter did not assess the seriousness or causality of the events in relationship to Eligard and Eligard unspecified device.

On 18-SEP-2023, follow-up information was received by Adium (reference number: SV-ADIUM-SV-0036-20230911) via email from the Patient Support Program "ASOFARMA A TU LADO" from a Consumer/Other Non-Health Prof and sent to Tolmar on 19-SEP-2023. New information included details of radiotherapy. on 25-SEP-2023, upon internal review, progression was not reported, prostate cancer was deleted.

It was confirmed that Radiotherapy was to treat prostate cancer and patient´s treatment was for 25 radiotherapies.

No further details were provided.

On 13-Jun-2025, follow-up information was received by Adium (reference number: SV-ADIUM-SV-0036-20230911(2)) via an electronic form through the Jazz Safety tool of
the Patient Support Program “ASOFARMA A TU LADO” from a Consumer/Other Non-Health Prof and sent to Tolmar on 24-Jun-2025. New information included suspect drug detail (Eligard treatment start date), non-serious event "Discontinuation of medication" (therapy cessation) was added.

On 03-Jul-2023, the patient began receiving Eligard 22.5 milligram, q 3 month, via subcutaneous route, for prostate cancer (Lot numbers and Expiration dates were unknown)

On an unknown date, the patient reported discontinuing medication.

Corrective treatment was unknown.

Action taken with Eligard in response to the event was unknown. De-challenge and re-challenge were not applicable.

The outcome of therapy cessation was unknown.

The reporter did not assess the seriousness of event therapy cessation.

The reporter assessed the causality of therapy cessation in relationship to Eligard and Eligard unspecified device as not related.

No further queries were raised.

On 06-Aug-2025, follow-up information was received by Adium via ASOFARMA A TU LADO Patient Support Program (reference number: SV-ADIUM-SV-0036-20230911 (3)) from a consumer (non-healthcare professional) and sent to Tolmar on 07-Aug-2025. New information included: Added onset date of the event "Therapy cessation" and Eligard 22.5 mg dose details. Narrative was updated.

On 28-Mar-2025, the patient reported discontinuing medication.

Continuation Sheet for CIOMS report

On 28-Apr-2025, the patient completed the treatment with Eligard 22.5 milligram, q 3 month, via subcutaneous route, for prostate cancer (Lot numbers and Expiration dates were unknown). No further details were available.

No further information is expected as consent to be contacted was not provided.

Listedness of previously reported events feeling hot and hyperhidrosis were retained as previously assessed.

Therapy cessation>Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Therapy cessation> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Therapy cessation> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Therapy cessation> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator Comment (Tolmar): This is regarding a 78-year-old male patient who received radiotherapy for prostate cancer (prostate cancer), experienced feeling hot (began to feel very hot) and hyperhidrosis (sweating) during Eligard (Leuprolide acetate) 22.5 mg therapy for cancer of prostate. Tolmar assessed the event prostate cancer as serious (medically significant) based on the reported significant treatment (radiotherapy), while all other events are considered as non-serious as there is no immediate jeopardy reported and did not meet ICH seriousness criteria. As per the case context and product safety profile events felling hot and hyperhidrosis are considered as related to Eligard (drug). More clinical information is needed to ascertain the causality of the event prostate cancer as the information regarding radiotherapy treatment is limited and hence considered as not related to Eligard (drug). All the events are considered as not related to device component of Eligard. Upon follow up event prostate cancer was deleted as progression was not reported.

FU added event of therapy cessation (discontinuation of medication). Tolmar assessed the reported event as non-serious since it did not meet the ICH seriousness criteria. The causality of event therapy cessation was assessed as not related to suspect Eligard(drug and device) as the event occurred due to human action and not due to drug.

FU-Causality of previously reported events feeling hot and hyperhidrosis were retained as previously assessed.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	:	Eligard® (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
		2) Injection
Lot Number	:	1) Unknown
		2) Unknown
Daily Dose	:	(22.5 milligram(s), 1 in 3 Month)
		(22.5 milligram(s), 1 in 3 Month)
Route of Admin	:	1) Subcutaneous
		2) Subcutaneous
Indications	:	1) prostate cancer [10007113 - Cancer of prostate]
Therapy Dates	:	1) From : 03/Jul/2023 To :Unknown
		2) From : To :28/Apr/2025
Action(s) Taken With Drug	:	Unknown

Causality

1) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING (Sensation of heat - 10039999, Feeling hot - 10016334)

Causality as per reporter	:	Not Reported
Causality as per Mfr	:	Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

2) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING (Sweating - 10042661, Hyperhidrosis - 10020642)

Causality as per reporter	:	Not Reported
Causality as per Mfr	:	Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

3) Discontinuation of medication (Therapy cessation - 10065154, Therapy cessation - 10065154)

Causality as per reporter	:	Not Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable

Continuation Sheet for CIOMS report

ReChallenge : Not Applicable

Labeling :

1) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING
CORE UnLabeled
2) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING
CORE Labeled
3) Discontinuation of medication
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) prostate cancer [10007113 - Cancer of prostate]
Action(s) Taken With Drug : Not applicable

Causality

1) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING (Sensation of heat - 10039999, Feeling hot - 10016334)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING (Sweating - 10042661, Hyperhidrosis - 10020642)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
3) Discontinuation of medication (Therapy cessation - 10065154, Therapy cessation - 10065154)
Causality as per reporter : Not Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING
CORE
2) BEGAN TO FEEL VERY HOT (SENSATION OF HEAT) AND SWEATING
CORE
3) Discontinuation of medication
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) 22.5 milligram, q 3 month, 22.5 MG x 1 LIO x 2 JER

2) 22.5 milligram, q 3 month, 22.5 MG x 1 LIO x 2 JER